Soon, the rules for volume-based drug procurement by the healthcare insurance system and the drug administration were officially released.
All those participating in this new drug tender needed to provide the first phase of drugs for free, which would then be allocated by the drug administration and healthcare insurance to various major hospitals in the provincial capital for double-blind experiments.
The so-called double-blind means that neither the doctors nor the patients knew which specific drug they were taking. After all psychological effects and subjective feelings were excluded, the conditions for taking different drugs were recorded.
In this way, the effectiveness of the drugs tested would be more credible, a necessary stage for new drugs to enter the market.
However, for Su Wen and others, this double-blind test was not only a validation before the new drug launch but also a simultaneous test for healthcare treatment pricing.
